Integer (NYSE:ITGR) Stock Price Expected to Rise, Benchmark Analyst Says

Integer (NYSE:ITGR) had its target price hoisted by analysts at Benchmark from $140.00 to $150.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. Benchmark’s price target points to a potential upside of 15.42% from the stock’s current price.

Several other research analysts also recently weighed in on ITGR. Truist Financial upped their price target on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Piper Sandler restated an “overweight” rating and set a $140.00 price target (up previously from $125.00) on shares of Integer in a research report on Friday, October 25th. Wells Fargo & Company restated an “overweight” rating and set a $160.00 price target on shares of Integer in a research report on Tuesday, December 3rd. Citigroup upped their price target on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Finally, Oppenheimer downgraded shares of Integer from an “outperform” rating to a “market perform” rating in a research report on Friday. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $147.67.

Integer Trading Down 3.9 %

ITGR stock opened at $129.96 on Friday. The company’s 50-day simple moving average is $137.74 and its 200-day simple moving average is $132.44. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer has a 52-week low of $98.63 and a 52-week high of $146.36. The firm has a market cap of $4.36 billion, a P/E ratio of 38.68, a PEG ratio of 1.72 and a beta of 1.13.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The firm had revenue of $449.50 million for the quarter, compared to analysts’ expectations of $446.28 million. As a group, equities analysts forecast that Integer will post 6.01 EPS for the current fiscal year.

Institutional Trading of Integer

A number of hedge funds have recently bought and sold shares of the business. Vise Technologies Inc. grew its stake in shares of Integer by 8.3% in the 4th quarter. Vise Technologies Inc. now owns 4,702 shares of the medical equipment provider’s stock valued at $623,000 after buying an additional 362 shares during the period. Squarepoint Ops LLC boosted its position in shares of Integer by 25.7% during the 4th quarter. Squarepoint Ops LLC now owns 3,162 shares of the medical equipment provider’s stock worth $419,000 after purchasing an additional 646 shares during the period. Teza Capital Management LLC boosted its position in shares of Integer by 11.6% during the 4th quarter. Teza Capital Management LLC now owns 2,727 shares of the medical equipment provider’s stock worth $361,000 after purchasing an additional 284 shares during the period. ProShare Advisors LLC boosted its position in shares of Integer by 44.4% during the 4th quarter. ProShare Advisors LLC now owns 10,051 shares of the medical equipment provider’s stock worth $1,332,000 after purchasing an additional 3,091 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Integer by 3.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,678 shares of the medical equipment provider’s stock worth $2,740,000 after purchasing an additional 685 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.